Hims & Hers Health Management

Management criteria checks 2/4

Hims & Hers Health's CEO is Andrew Dudum, appointed in Jan 2017, has a tenure of 7.33 years. total yearly compensation is $14.40M, comprised of 4.2% salary and 95.8% bonuses, including company stock and options. directly owns 9.13% of the company’s shares, worth €262.90M. The average tenure of the management team and the board of directors is 2.2 years and 3.2 years respectively.

Key information

Andrew Dudum

Chief executive officer

US$14.4m

Total compensation

CEO salary percentage	4.2%
CEO tenure	7.3yrs
CEO ownership	9.1%
Management average tenure	2.2yrs
Board average tenure	3.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Andrew Dudum's remuneration changed compared to Hims & Hers Health's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$2m
Dec 31 2023	US$14m	US$612k	-US$24m
Sep 30 2023	n/a	n/a	-US$36m
Jun 30 2023	n/a	n/a	-US$47m
Mar 31 2023	n/a	n/a	-US$59m
Dec 31 2022	US$11m	US$600k	-US$66m
Sep 30 2022	n/a	n/a	-US$86m
Jun 30 2022	n/a	n/a	-US$83m
Mar 31 2022	n/a	n/a	-US$73m
Dec 31 2021	US$15m	US$574k	-US$108m
Sep 30 2021	n/a	n/a	-US$82m
Jun 30 2021	n/a	n/a	-US$72m
Mar 31 2021	n/a	n/a	-US$63m
Dec 31 2020	US$27m	US$527k	-US$18m
Sep 30 2020	n/a	n/a	-US$25m
Jun 30 2020	n/a	n/a	-US$38m
Mar 31 2020	n/a	n/a	-US$58m
Dec 31 2019	US$254k	US$254k	-US$72m

Compensation vs Market: Andrew's total compensation ($USD14.40M) is above average for companies of similar size in the German market ($USD2.36M).

Compensation vs Earnings: Andrew's compensation has increased whilst the company is unprofitable.

CEO

Andrew Dudum (34 yo)

7.3yrs

Tenure

US$14,401,411

Compensation

Mr. Andrew Dudum serves as Chairman of the Board and serves as Chief Executive Officer at Hims & Hers Health, Inc. since January 20, 2021. He Co-Founded Hims & Hers Health, Inc. in 2017. He is Co-founded H...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Andrew Dudum	Co-Founder	7.3yrs	US$14.40m	9.13% $ 262.9m
Yemi Okupe	Chief Financial Officer	2.3yrs	US$7.43m	0.079% $ 2.3m
Melissa Baird	Chief Operating Officer	3.3yrs	US$6.77m	0.25% $ 7.2m
Soleil Boughton	Chief Legal Officer & Corporate Secretary	3.3yrs	US$5.21m	0.074% $ 2.1m
Patrick Carroll	Chief Medical Officer	1.4yrs	US$198.26k	0.081% $ 2.3m
Mike Chi	Chief Commercial Officer	less than a year	US$6.71m	0.082% $ 2.4m
Irene Becklund	Senior VP	4.9yrs	US$961.12k	0% $ 0
Khobi Brooklyn	Chief Communications Officer	less than a year	no data	no data
Amee Parekh	Senior Vice President of Human Resources	2.2yrs	no data	no data
Peter Stahl	Senior VP & Member of Medical Advisory Board	no data	no data	no data
Scott Knoer	Chief Pharmacy & Innovation Officer	1.4yrs	no data	no data
Daniel Lieberman	Senior Vice President of Mental Health	1.2yrs	no data	no data

2.2yrs

Average Tenure

43yo

Average Age

Experienced Management: 82W's management team is considered experienced (2.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Andrew Dudum	Co-Founder	3.3yrs	US$14.40m	9.13% $ 262.9m
Patrick Carroll	Chief Medical Officer	2.3yrs	US$198.26k	0.081% $ 2.3m
Peter Stahl	Senior VP & Member of Medical Advisory Board	2.3yrs	no data	no data
Delos Cosgrove	Independent Director	3.7yrs	US$194.26k	0.016% $ 464.8k
Lynne O'Keefe	Independent Director	3.5yrs	US$206.76k	0% $ 0
Alex Bard	Independent Director	3.3yrs	US$203.63k	0.060% $ 1.7m
Ambar Bhattacharyya	Independent Director	less than a year	US$209.76k	0.033% $ 955.3k
David Wells	Lead Independent Director	3.7yrs	US$227.41k	0.073% $ 2.1m
Andrea Perez Garcia	Independent Director	3.2yrs	US$205.51k	0.025% $ 710.6k
Amy Voedisch	Member of Medical Advisory Board	2.4yrs	no data	no data
Lawrence Jenkins	Member of Medical Advisory Board	no data	no data	no data
Bertha Chen	Member of Medical Advisory Board	2.4yrs	no data	no data

3.2yrs

Average Tenure

50yo

Average Age

Experienced Board: 82W's board of directors are considered experienced (3.2 years average tenure).

Hims & Hers Health Management

Management criteria checks 2/4

Key information

Recent management updates

Hims & Hers Health, Inc. Appoints Anja Manuel to its Board of Directors

Hims & Hers Appoints Christopher Payne as Newest Board Member

Lead Independent Director recently sold €3.2m worth of stock

Hims & Hers Names Dan Kenger as the Company’s First Chief Design Officer

Hims & Hers Health, Inc. Names Khobi Brooklyn as Chief Communications Officer

Hims & Hers Health, Inc. Appoints Ambar Bhattacharyya to Directorate

Recent updates

Hims & Hers Health, Inc. Appoints Anja Manuel to its Board of Directors

Hims & Hers Health, Inc. Announces Impairment Charges for the First Quarter Ended March 31, 2024

First quarter 2024 earnings released: EPS: US$0.052 (vs US$0.049 loss in 1Q 2023)

Hims & Hers Health, Inc. to Report Q1, 2024 Results on May 06, 2024

Hims & Hers Appoints Christopher Payne as Newest Board Member

Lead Independent Director recently sold €3.2m worth of stock

Hims & Hers Health, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Full year 2023 earnings released: US$0.11 loss per share (vs US$0.32 loss in FY 2022)

Forecast breakeven date moved forward to 2024

Hims & Hers Names Dan Kenger as the Company’s First Chief Design Officer

Hims & Hers Health, Inc. to Report Q4, 2023 Results on Feb 26, 2024

Hims & Hers Health, Inc. Launches Holistic Weight Loss Program to Break the Endless Cycle of Weight Gain and Loss

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.036 loss per share (vs US$0.092 loss in 3Q 2022)

Hims & Hers Health, Inc. Provides Revenue Guidance for the Full Year 2023

Hims & Hers Health, Inc. Names Khobi Brooklyn as Chief Communications Officer

Hims & Hers Health, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Hims & Hers Health, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023

Second quarter 2023 earnings released: US$0.034 loss per share (vs US$0.096 loss in 2Q 2022)

Hims & Hers Health, Inc. to Report Q2, 2023 Results on Aug 07, 2023

New major risk - Share price stability

Hims & Hers Health, Inc. Unveils Innovative Line of Personalized Solutions

Hims & Hers Health, Inc. Appoints Ambar Bhattacharyya to Directorate

Hims & Hers Health, Inc. Reports Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2023

Forecast breakeven date moved forward to 2024

First quarter 2023 earnings released: US$0.048 loss per share (vs US$0.08 loss in 1Q 2022)

Chief Medical Officer recently sold €229k worth of stock

Full year 2022 earnings released: US$0.32 loss per share (vs US$0.58 loss in FY 2021)

Hims Launches Hard Mints – A Highly Treatment for Erectile Dysfunction

Hims & Hers Health, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Hims & Hers Health, Inc. Launches New Line of Volumizing Shampoos and Conditioners

Forecast to breakeven in 2025

Hims & Hers Appoints Dr. Pat Carroll as Chief Medical Officer

Hims & Hers Health, Inc Appoints Scott Knoer as Chief Pharmacy & Innovation Officer

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.092 loss per share (vs US$0.08 loss in 3Q 2021)

Hims & Hers Health, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

Hims & Hers Health, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Hims & Hers Health, Inc. Appoints Brian O’Shaughnessy as First Chief Communications Officer

Hims & Hers Launches New Android Apps

Hims & Hers Health, Inc. Provides Earnings Guidance for the Third Quarter of 2022

Second quarter 2022 earnings released: US$0.096 loss per share (vs US$0.048 loss in 2Q 2021)

Hims & Hers Health, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Lead Independent Director recently bought €187k worth of stock

Hims & Hers Health, Inc. Announces Launch of 6 New Hers Wellness Essentials Supplements

No longer forecast to breakeven

Hims & Hers Health, Inc. Revises Earnings Guidance for the Full Year 2022

Hims & Hers Health, Inc., Annual General Meeting, Jun 02, 2022

High number of new and inexperienced directors

Hims & Hers Health, Inc. to Report Q1, 2022 Results on May 09, 2022

Hims & Hers Doubles Skincare Product Offerings with A Suite of New Products

Principal Accounting Officer recently sold €69k worth of stock

Hims & Hers Health, Inc. Appoints Amee Parekh as Senior Vice President of Human Resources

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Hims & Hers Health, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2022

Hims & Hers Launches New Line of Mental Wellness Supplements, with More Options to Help Support Stress, Sleep and Lack of Focus

Hims & Hers Health, Inc. to Report Fiscal Year 2021 Results on Feb 22, 2022

Hims & Hers Health, Inc. Introduces New Prescription Dermatology Offerings Increasing Support for Women Experiencing Common Yet Emotionally Distressing Hair Loss

Co-Founder recently bought €426k worth of stock

Third quarter 2021 earnings released: US$0.08 loss per share (vs US$0.074 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.045 loss per share (vs US$0.008 loss in 2Q 2020)

Hims & Hers Health, Inc. Expands Mental Health Offerings to Include Individual Online Therapy

Hims & Hers Health, Inc. (NYSE:HIMS) entered into a letter of interest to acquire Apostrophe, Inc.

Hims & Hers Health, Inc. Expands Hair Growth Offerings with Launch of Minoxidil 5% Foam

Hims & Hers Health, Inc. (NYSE:HIMS) agreed to acquire Honest Health Limited.

Hims & Hers Now Offering a Dual-Action Topical Hair Loss Treatment for Men

Hims & Hers Health, Inc. Partners with Alex Rodriguez to Launch Blur Stick Concealer

First quarter 2021 earnings released: US$0.34 loss per share (vs US$0.17 loss in 1Q 2020)

Forecast to breakeven in 2024